SRYAHWA PUBLICATIONS

Journal of International Politics
ISSN: 2642-8245 | Volume 7, Issue 3, 2026
https://doi.org/10.22259/2642-8245.0703001

RESEARCH ARTICLE

The Capacity to Return Adaptive Longevity Medicine, Commercial Epistemic Distortion, and a Clinical Framework for Healthy Aging

Julian Ungar-Sargon, MD, Ph.D

Former Clinical Director, PA Program, Borra College of Health Sciences, Dominican University, River Forest, Illinois, USA.

Received: 01 September 2026 Accepted: 17 September 2026 Published: 25 September 2026

Corresponding Author: Julian Ungar-Sargon, MD, Ph.D, Former Clinical Director, PA Program, Borra College of Health Sciences, Dominican University, River Forest, Illinois, USA.

Abstract

Geroscience has converted aging from a chronological given into a set of measurable and potentially modifiable biological processes. The hallmarks of aging, methylation clocks, proteomic organ clocks, and cell-type-specific aging signatures now allow biological age to be estimated independently of the calendar. Two problems accompany this achievement. The first is epistemological: a measurable biomarker can quietly become the definition of the state it was built to estimate. The second is economic: longevity science is maturing inside a commercial ecosystem that rewards patentable molecules, proprietary assays, repeat testing, and the conversion of ordinary aging into a treatable anxiety.

Objective: To propose a clinical framework for longevity that integrates contemporary geroscience with the geriatric traditions of intrinsic capacity and physical resilience, and that names, with appropriate precision, the way commercial incentives shape which questions about aging become scientifically visible.

Discussion: I propose the term *commercial epistemic distortion* for the structural condition in which economic incentives influence which questions are funded, which endpoints are privileged, how results are disseminated, and which interventions achieve clinical prominence. The term is deliberately narrower than fraud and does not imply that industry-sponsored science is invalid. Against this background I propose *Adaptive Longevity Medicine* (ALM), whose central construct is *adaptive coherence*: the capacity of a person, understood as an integrated biological, psychological, and relational system, to absorb perturbation, coordinate a compensatory response, recover toward a prior or viable functional state, and preserve meaningful agency over time. ALM shifts the primary clinical measurement from state to *recovery kinetics* — what happens to the organism after it is disturbed, how fast it returns, how completely, and whether its systems return together. Nine domains are described, together with a four-level, deliberately non-proprietary Adaptive Coherence Profile and a falsifiable four-phase research program.

Conclusion: Healthy longevity is not a younger biomarker profile. It is the retained capacity to recover, function, relate, and pursue what one values. The organizing question of longevity medicine should therefore move from *How old is this organism biologically?* to *When life disturbs the system, how much of this person comes back?*

Keywords: Aging, Longevity, Healthspan, Geroscience, Resilience, Intrinsic Capacity, Biological Aging Clocks, Frailty, Convalescence, Commercial Determinants Of Health, Recovery, Hermeneutic Medicine.

Citation: Julian Ungar-Sargon, The Capacity to Return Adaptive Longevity Medicine, Commercial Epistemic Distortion, and a Clinical Framework for Healthy Aging. Journal of International Politics. 2026;7(3): 01-18.



1. Introduction: The Question Longevity Medicine Has Not Yet Answered

For most of its history medicine has approached aging obliquely, treating its diseases one at a time and leaving the underlying process unexamined. Geroscience proposes something more ambitious and, in my view, correct: that the biological processes driving aging contribute simultaneously to many chronic diseases and may therefore be addressed upstream, before each disease declares itself [1]. The scientific foundation for this claim has become formidable. The expanded hallmarks described by López-Otín and colleagues — genomic instability, telomere attrition, epigenetic alteration, loss of proteostasis, disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem-cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis — describe not a single failing mechanism but a network of interacting ones [2].

Measurement has advanced even faster than mechanism. Wyss-Coray and Topol's recent appraisal in *Nature Medicine* documents a field in which methylation, proteomic, imaging-derived, and cell-type-specific clocks can now estimate the pace of aging of a person, an organ, or a cell population [3]. Plasma proteomic work has shown that organs age asynchronously within the same body, so that a person may carry a young heart and an old brain, or the reverse [4]. This is a genuine and remarkable achievement, and nothing in what follows should be read as diminishing it.

But a clinician reading this literature has to ask a question the literature does not itself answer.

1.1 What, Precisely, is Longevity Medicine Trying to Preserve?

If the answer is a molecular profile resembling that of a younger person, then clinical longevity will organize itself around biomarkers and around the interventions that move them, because that is what the answer implies. If the answer is healthy aging, then a molecular change matters only insofar as it predicts or produces something else: preserved cognition, preserved mobility, preserved independence, resistance to illness, recovery after illness, participation in a life the patient recognizes as their own. These two answers look similar in a laboratory and diverge completely in a clinic. The distinction is not semantic; it determines what we measure, what we study, what industry develops, and — this is the part rarely said aloud — what patients are sold.

The World Health Organization moved geriatric medicine away from a purely disease-centered model when it defined healthy aging as the development and maintenance of the functional ability that enables well-being, and introduced the composite notion of intrinsic capacity [5]. More recently Cohen, Picard, Fried, Belsky, and colleagues have proposed *intrinsic health* as an emergent biological property expressed through resilience, plasticity, performance, and sustainability [6]. Aging science is thus already drifting from a model of accumulated damage toward one interested in capacity, dynamics, and return. This paper is an attempt to complete that drift and give it a clinical form.

The proposal cannot be made honestly without also describing the economic environment in which longevity science is being built. Aging is an extraordinary market. The eligible population is every adult. The treatment interval is the remainder of life. The relevant anxiety — decline, dependence, death — is universal and easily monetized. And the endpoints are conveniently repeatable: a biological-age test can be sold quarterly forever, whereas disability-free survival takes decades to observe. Longevity clinics have appeared across the United States, Switzerland, Singapore, and the Gulf offering multi-omic profiling, full-body imaging, hormone regimens, peptides, plasma exchange, and stem-cell infusions; Demaria,

writing as editor of *Aging*, notes bluntly that in too many of these settings commercial incentives have overtaken scientific rationale, and that the diagnostics themselves are frequently misinterpreted [7]. The broader framework of the commercial determinants of health describes how corporate structures shape not only products but research agendas and public understanding [8].

I have written before about the distorting effect of profit on clinical evidence and on the moral architecture of medicine [9]. I have also written about a small and neglected clinical territory — convalescence, the interval between illness and health that modern systems no longer name [10]. This paper joins those two lines of work to the geroscience literature and argues that the interval I once described in a minor key is, in aging, the major variable.

2. What the Science Actually Shows

2.1 Clocks, Organs, and Cells

The technical achievement is real and should be stated generously before it is qualified. DNA methylation clocks estimate biological age or, in the case of DunedinPACE, the *rate* at which biological aging is proceeding within an individual [11]. Plasma proteomic models have extended this to individual organs, and the Whitehall II cohort has shown that organ-specific proteomic aging signatures predict age-related disease risk over two decades of follow-up [12]. Wyss-Coray and Topol summarize the state of play carefully: these clocks have plausible use cases in risk stratification, early detection, and the evaluation of interventions, and their eventual clinical value will depend not on predictive accuracy alone but on demonstrated clinical utility — evidence that knowing a biological age changes what a clinician does and improves what happens to the patient [3].

That last condition is the entire problem, and it is worth dwelling on because it is routinely skipped in the consumer-facing translation of this science.

2.2 Three Roles a Biomarker can Occupy

A biomarker of aging can occupy at least three distinct epistemological positions, and the confusion of these positions is the central error of commercial longevity practice.

It may be a **marker of state**: a description of where the organism currently is. It may be a **predictor of risk**: an association with future outcomes strong enough to inform prognosis. Or it may be a **validated surrogate target**: a variable whose modification reliably produces the clinical benefit we actually want. These are not interchangeable. A clock may predict mortality without being a mechanism of mortality. An intervention may move a clock without extending disability-free survival. An intervention may extend disability-free survival while barely moving a clock.

The Biomarkers of Aging Consortium has made this point repeatedly and with more authority than I can claim, setting out what validation requires — analytical validity, reproducibility, biological plausibility, prospective association with meaningful outcomes, and, for surrogacy, evidence that intervention-induced change predicts clinical change — and cautioning explicitly that these criteria are not yet met for routine clinical implementation [13,14,15]. The people closest to the technology are the most careful about it. The caution attenuates as the science travels outward toward the market.

2.3 A Worked Example: CALERIE

The CALERIE trial provides the cleanest available illustration. In a post hoc analysis of a randomized trial of two years of 25% caloric restriction in 220 adults without obesity, the intervention slowed DunedinPACE but produced no significant change in the PhenoAge or GrimAge methylation clocks [16].

Consider what a clinician is entitled to conclude from this. Three algorithms, all built from methylation data drawn from the same blood samples of the same randomized participants, disagreed about whether the intervention had affected aging. This is not a criticism of the trial, which was conducted and reported with exemplary care. It is an observation about the ontological status of the measurement. If three clocks disagree, then at least two of them are not measuring "aging" as such; they are measuring correlated but distinct biological phenomena that we have collectively agreed to label with the same word. And when a commercial laboratory returns a single number to a patient — "your biological age is 52" — the number conceals precisely this disagreement, along with the choice of algorithm, reference population, tissue, and assay platform that produced it.

I have argued elsewhere, in the context of depression research, that biomedical reductionism fails not because molecules are unimportant but because a molecular index is repeatedly mistaken for the condition it indexes [17]. The same error, which I have traced in its longer philosophical form to the

persistence of Cartesian assumptions in clinical practice [18], is now being made in aging with better instruments and greater confidence.

The appropriate response is not skepticism toward the technology. It is epistemic discipline about what the technology has and has not established. The clinical question must remain: **does changing this measure predictably change something that matters to this patient?**

3. Commercial Epistemic Distortion

3.1 Why "Corruption" is the Wrong Word

I have written critically, and at times sharply, about the pharmaceutical industry, about the incentives that structure prescribing, and about the moral consequences of organizing care around profit [9,19,20,21]. I want here to make the argument more precise than I have sometimes made it, because precision serves the critique better than force does.

Most biomedical researchers are not falsifying data. Most industry-sponsored trials are not fraudulent. To describe medical science as corrupt is both inaccurate and strategically self-defeating: it allows the entire critique to be dismissed with a single counterexample. The defensible claim is structural rather than moral, and it is well supported.

A Cochrane review of the sponsorship literature found that industry-sponsored drug and device studies were more likely than non-industry-sponsored studies to report efficacy results and conclusions favoring the sponsor's product [22]. Turner and colleagues, comparing published antidepressant trials against the corresponding FDA regulatory dataset, demonstrated that selective publication alone could make a body of evidence look substantially more favorable than it was [23]. Ioannidis showed two decades ago how prior odds, flexibility of design, and competitive financial pressure combine to make a high proportion of published findings unreliable [24]. None of this requires anyone to lie.

3.2 The Definition

For the purposes of aging medicine I propose the following:

Commercial epistemic distortion is a systematic alteration in the production, visibility, interpretation, or clinical priority of knowledge, arising when economic incentives preferentially reward certain questions, endpoints, interventions, or representations of health and disease.

It does not require fraud. It does not require conspiracy. It does not require any individual investigator to behave dishonestly. It arises from the arrangement of incentives, and it operates at four distinguishable levels.

Agenda distortion determines which questions are asked. An intervention that is patentable, scalable, repeatedly administered, and paired with a measurable surrogate attracts capital; an intervention involving neighborhood design, hearing aids for the poor, exercise adherence, bereavement support, or the reduction of loneliness does not. Over time the literature becomes exquisitely detailed exactly where the money is and thin exactly where it is not.

Endpoint distortion determines what counts as success. When definitive outcomes take decades, surrogates become attractive; when surrogates become commercially measurable, they begin to substitute for the outcome rather than approximate it.

Dissemination distortion determines what becomes visible, through selective publication, conference emphasis, and press release [22,23].

Ontological distortion is the last and the most consequential: what is easily measured begins to seem more real than what is not. I have described the analogous mechanism in clinical judgment, where measurement, language, and institutional power together determine which forms of knowledge are recognized as legitimate [25], and in the way institutions manufacture and then defend their own truths [26]. Latour's insight, which I have applied to medical hierarchies, is apposite here: the instrument does not merely record the network, it helps constitute it [27].

The asymmetry can be stated in a sentence that I take to be the ethical center of this paper:

3.2.1 The Commercial Value of an Intervention and its Importance to Human Health are Independent Variables.

3.3 Why Longevity is Unusually Exposed

Every structural condition that produces distortion is maximal in aging medicine. The market is universal. The product is indefinite. The endpoint is remote. The surrogate is repeatable and can be returned to the consumer as a single, emotionally charged number. The anxiety is existential and therefore inelastic to price. And the field is young enough that professional norms, registries, and reporting standards have not yet consolidated [7].

There is also a specific hazard for a paper such as this one. A framework that criticizes commercial reductionism can itself be commercialized. Any construct I propose here could be assembled into a proprietary score, trademarked, and sold at $2,000 a year. I therefore state as a condition of the proposal that the Adaptive Coherence Profile described in Section 7 should remain open, published in full, and free to replicate — and that if it cannot survive independent validation it should be abandoned rather than marketed. I have written elsewhere about the difficulty of holding a boundary between dialogical clinical practice and pseudoscience [28]; the discipline required is the same here, and it applies to my own proposals first.

4. Recovery: The Variable Geriatrics Already knows about

Geriatric medicine possesses, and has possessed for a quarter century, the concept that bridges molecular aging and lived health. It has simply never been placed at the center of the longevity conversation.

Frailty, as operationalized by Fried and colleagues, describes a phenotype of diminished physiological reserve and heightened vulnerability [29]. Physical resilience refines this further: it is the ability of an older adult to resist functional decline or to recover following a health stressor. Gijzel and colleagues argued that static measures of reserve inadequately characterize resilience precisely because resilience is a dynamic property, visible only in response to disturbance [30]. Colón-Emeric and colleagues have gone further and specified the methodology: repeated measurement before, during, and after a stressor, so that the recovery trajectory itself becomes the observation [31]. WHO intrinsic capacity, meanwhile, supplies the multidimensional inventory of what there is to recover [5,32].

This literature has not yet met the geroscience literature in any serious way. My argument is that their meeting point is the clinical event every physician who cares for older people already recognizes.

4.1 Medicine Measures States; Organisms Live in Time

Consider what we actually record: blood pressure, glucose, weight, C-reactive protein, gait speed, grip strength, muscle mass, cognitive score, methylation age. Every one of these is a state — a photograph of an equilibrium. But equilibrium is the condition under which a biological system reveals the least about itself. A system discloses its reserve when it is disturbed.

Take two women of seventy-eight with identical resting heart rates, blood pressures, fasting glucose, HbA1c, and gait speed. Both develop influenza. One is unwell for nine days, tired for another two weeks, and by six weeks is walking her usual route at her usual pace. The other is unwell for nine days, becomes deconditioned, falls once, stops driving because she no longer trusts herself at dusk, loses four kilograms she does not regain, and one year later has not returned to her prior mobility or her prior life. Her daughter now shops for her.

Their static measurements were indistinguishable. Their adaptive capacity was not. And there is at present no line in the chart, and no assay on any longevity panel, that captured the difference before the influenza arrived.

4.2 Post-Hospital Syndrome and the Biology of not Returning

The clinical literature has documented this asymmetry repeatedly without naming it as a property of aging. Krumholz described post-hospital syndrome as an acquired, transient period of generalized risk following hospitalization — a state in which the patient is vulnerable not primarily because of the illness that brought them in but because of the deconditioning, sleep disruption, nutritional depletion, and physiological stress of the admission itself [33]. Covinsky and colleagues showed that a substantial proportion of older adults hospitalized for medical illness lose independence in activities of daily living, with vulnerability increasing steeply with age [34]. Gill and colleagues demonstrated that hospitalization and even restricted activity at home mark inflection points in the disability trajectory, after which many older persons simply do not return to their previous level of function [35]. Delirium, the most visible form of this failure, is both a marker of vulnerable reserve and an independent cause of subsequent decline [36].

Medicine currently reads these findings as complications of hospitalization. I want to propose that they are also *measurements of aging* — perhaps the most clinically informative measurements we possess, and certainly the ones we have already been collecting without recognizing what they tell us.

4.3 Convalescence

The disappearance of convalescence from modern medicine is not merely a loss of a nineteenth-century

social institution. I argued some years ago that health systems now sort patients into the binary categories of sick and well, and that in doing so they have abolished the interval in which recovery actually takes place [10]. The older concept understood something we have forgotten: that the absence of acute disease is not the restoration of capacity.

An eighty-two-year-old man is discharged after community-acquired pneumonia. His oxygen saturation is normal, his white count has normalized, his chest film is improving, his antibiotics are complete. By every criterion in the discharge summary he has been treated. He is also four kilograms lighter, unable to rise from a low chair without pushing, sleeping in three-hour fragments, mildly disinhibited in a way his wife notices and the hospital did not, and frightened. From the disease model he is cured. From a resilience model, his system has not come back, and the clock on his return has already started running against him.

This suggests a different ontology of aging, which I state as the paper's central biological proposition:

4.3.1 Aging May be Expressed Clinically as Progressively Slower, Less Coordinated, and Less Complete Recovery Following Perturbation.

Repeated insults with incomplete recovery generate a descending staircase: stressor, partial recovery, reduced reserve, next stressor, further incomplete recovery, frailty, disability, dependence. This does not displace any molecular mechanism. It is the phenotype through which many molecular mechanisms plausibly converge and become visible to a clinician at the bedside. It also has a temporal structure that I have argued elsewhere is central to a mature clinical practice: the therapeutic space is not a point but a duration, and it must be attended to over horizons appropriate to the patient's stage of life [37]. The patient's history, properly taken, is already an account of returns and failures to return [38].

5. Adaptive Longevity Medicine

I propose the term **Adaptive Longevity Medicine (ALM)** for a clinical approach in which the preservation of adaptive capacity, rather than the optimization of an aging biomarker, becomes the principal objective of healthy aging.

Its central construct is **adaptive coherence**.

Adaptive coherence is the capacity of a person — understood as an integrated biological, psychological, and relational system — to tolerate perturbation, coordinate compensatory responses across systems, recover toward a prior or viable functional state, and preserve meaningful agency over time.

The word *adaptive* insists that the object of measurement is a response, not a state. The word *coherence* insists that health depends on coordination among systems rather than the maximal performance of each in isolation. A patient whose cardiovascular recovery is excellent, whose cognition returns promptly, and whose immune resolution is intact, but whose social world has collapsed and who therefore does not eat, is not adaptively coherent. Coordination is the property, and it is lost domain by domain in ways the current panel of measurements does not reveal.

5.2 Relation to Existing Constructs

ALM is not a competitor to established geriatric science. It is an attempt to integrate four bodies of work that have grown up separately.

Frailty describes vulnerability arising from diminished reserve [29]. Adaptive coherence asks how that vulnerability behaves in time — how the frail system actually fails and recovers when it is struck.

Intrinsic capacity describes the composite of physical and mental capacities available to the individual [5,32]. Adaptive coherence adds the temporal derivative: not what capacity exists, but how it changes and returns after stress.

Physical resilience is the closest operational relative, and my debt to Gijzel, Whitson, Colón-Emeric, and colleagues is direct [30,31]. Adaptive coherence extends resilience beyond the physical to metabolic, autonomic, immune, cognitive, interoceptive, relational, and value-defined domains, and asks a question resilience research has not yet formalized: whether these domains recover *together*.

Intrinsic health is the closest theoretical relative, conceptualizing health through resilience, plasticity, performance, and sustainability [6]. Adaptive coherence translates that systems-biological framework into an explicitly clinical aging model organized around longitudinal recovery trajectories that a working physician could actually observe.

6. The Domains of Adaptive Coherence

Adaptive coherence is proposed as a multidimensional profile, not a score. The premature compression of these domains into a single number would reproduce exactly the reductionism the model exists to resist.

6.1 Metabolic Adaptability

A fasting glucose is useful. But metabolic health is fundamentally about the capacity to respond appropriately to feeding, fasting, exertion, sleep loss, and illness, and to return to baseline afterward. Metabolic flexibility — the ability to shift substrate utilization according to demand — declines with age and with metabolic disease, and it declines before conventional thresholds are crossed.

The adaptive question is not *what is the glucose* but *how does the metabolic system respond and return following a challenge*. Candidate research measures include standardized postprandial trajectories, exercise-associated substrate responses, and, in research settings, continuous glucose monitoring interpreted as a recovery curve rather than as an average. I emphasize that none of these should be presumed clinically valuable merely because they are technologically available; the burden of prospective validation applies to my proposals exactly as it applies to methylation clocks.

6.2 Cardiovascular and Autonomic Adaptability

Cardiovascular reserve is unusually amenable to dynamic assessment because much of it is already standard practice in other contexts: heart-rate response to graded exertion, heart-rate recovery in the first and second minutes after exercise, orthostatic blood-pressure stabilization, heart-rate variability under standardized conditions, and time to return to resting parameters. An adaptive cardiovascular system responds proportionately to demand and then returns efficiently. The clinical information is in the return, and we routinely discard it.

6.3 Musculoskeletal and Physical Reserve

Movement may be the single most consequential expression of longevity. The LIFE randomized trial showed that structured physical activity reduced the incidence of major mobility disability in vulnerable older adults [39]; umbrella-level evidence supports a dose-response relationship between physical activity and all-cause mortality in this population [40]; and resistance training is independently associated with lower all-cause and disease-specific mortality [41].

ALM would go beyond documenting habitual activity. It would ask: how much reserve exists above the threshold required for independence? What happens to gait speed and chair-rise performance after a week in bed, a hospitalization, an operation? How much strength is lost, and over what interval is it regained, and is it regained at all? The trajectory of grip strength or gait speed across an illness is, I suspect, more informative than any single baseline value — and it is obtainable with a dynamometer and a stopwatch.

6.4 Immune Resilience and Inflammatory Resolution

Aging is accompanied by chronic low-grade inflammatory signaling, the phenomenon Ferrucci and Fabbri named inflammageing and linked to cardiovascular disease and frailty [42]. But inflammation is not intrinsically pathological; acute inflammation is the mechanism of defense and repair. The clinically important property is the capacity to mount a proportionate response and then to *resolve* it.

Ahuja and colleagues have described immune resilience as the preservation or restoration of immune competence during inflammatory stress, and have associated it with favorable health outcomes and longevity [43]. Adaptive coherence therefore does not aim at minimal inflammation. A quiescent immune system is not healthy, and a persistently activated one is not either. Health lies in the range and in the return.

6.5 Cognitive Adaptability

Cognition in aging is nearly always assessed at a single moment and under favorable conditions. Yet the clinically decisive property is cognitive resilience under load: the patient who scores 28 on the MoCA in the office and becomes floridly delirious on the second postoperative night has a cognitive system whose static measurement told us very little [36].

The proposed research outcomes are the magnitude and duration of cognitive change surrounding a stressor, and the completeness of cognitive return. This is directly relevant to identifying, before surgery or admission, the patients whose cognition will not fully come back. I have written about memory loss as a phenomenon requiring interpretation as well as measurement [44]; here the measurable and the interpretive coincide, because what the family reports about whether the person “came back” is data.

6.6 Interoceptive and Neurobehavioral Regulation

The nervous system continuously receives, integrates, and interprets signals from the interior of the body: hunger, fatigue, dyspnea, pain, cardiac sensation, visceral state, autonomic arousal. I have argued that clinical medicine becomes incomplete when bodily experience is treated as a secondary and unreliable

representation of an objective physiology that only instruments can access [45,46].

For aging, the implication is specific. Successful adaptation requires not merely intact physiological signaling but the capacity to perceive internal signals accurately and to act on them. Interoceptive dysregulation plausibly contributes to inactivity, anxiety, altered pain behavior, poor recognition of physiological limits, and the failure to seek care until decompensation. Whether interoceptive accuracy independently predicts adaptive recovery in older adults is, at present, a hypothesis. It enters ALM as a research domain and should be labeled as such rather than asserted.

6.7 Relational and Social Resilience

Human aging occurs inside a social system, and the physiology of an older person is not bounded by their skin. The largest available synthesis — 90 prospective cohorts and 2,205,199 participants — found social isolation associated with a 32% increase and loneliness with a 14% increase in all-cause mortality risk [47].

These are associations, and they do not establish that any particular social intervention extends life. They establish something sufficient for clinical purposes: relational conditions cannot be treated as external to aging biology. The clinically relevant variables include isolation, perceived support, caregiver availability and burden, community participation, bereavement, and — most relevant to this framework — the capacity to reconstitute social functioning after an illness. Many older patients recover physiologically and never recover socially; they leave the hospital and do not return to the choir, the shul, the card game, the volunteer shift. That is a failure of return, and it is measurable.

The therapeutic relationship belongs inside this domain. I have argued at length that the clinical encounter carries interpretive and relational weight not reducible to the transfer of biomedical information [48], and that the quality of listening measurably affects outcome [49]. I want to state the limit of that claim as clearly as I have stated the claim itself: nothing in this literature supports the proposition that compassion reverses methylation age. What it supports is more modest and quite sufficient — that trust, attention, and alliance affect disclosure, adherence, decision-making, perceived burden, and the manner in which a patient navigates the illness that will determine whether they recover.

6.8 Meaning and Patient-Valued Function

A medicine devoted to extending life eventually confronts a question molecular geroscience cannot answer from its own resources: *what is the additional life for?*

This is not only philosophical. A 2026 meta-analysis of 25 samples comprising 488,765 participants followed for up to 32 years found purpose in life associated with roughly a 30% lower risk of earlier mortality (HR 0.76), attenuated but persistent after adjustment for behavioral, clinical, and depressive risk factors [50]. As with all observational findings, confounding and reverse causation demand caution, and the authors themselves are appropriately restrained.

But the clinical importance of meaning does not depend on that hazard ratio. It depends on the fact that patients define successful aging in functional and biographical terms, never in molecular ones. They want to stay in the house. To recognize their grandchildren. To walk to the corner. To drive at night. To teach, to pray, to garden, to travel, to care for a spouse, to remain a member of something. The WHO definition already encodes this orientation by defining healthy aging as the functional ability to be and to do what people have reason to value [5].

Meaning therefore does not need to be defended as an anti-aging intervention. It belongs in longevity medicine because without it there is no definition of the life being preserved. My work on mortality awareness in chronic and degenerative disease [51] and on the patient's account as a text requiring interpretation rather than mere extraction [52] both bear on this: the physician who cannot say what the patient's remaining years are *for* is not in a position to say whether an intervention has helped.

6.9 Biological Aging Measures

Finally, the molecular clocks retain their place — as a domain, not as the definition [3,13]. Their proper question within ALM is inverted from the usual one. Not *has the clock improved?* but *do changes in this molecular measure correspond to changes in adaptive performance?*

Table 1. *Domains of Adaptive Coherence*

DOMAIN	CONVENTIONAL STATIC MEASURE	THE ADAPTIVE QUESTION	CANDIDATE DYNAMIC MEASURES
Metabolic	Glucose, HbA1c, lipids	*How efficiently does metabolism respond and return after challenge?*	Postprandial excursion and recovery slope; CGM-derived return kinetics; substrate response to exertion
Cardiovascular / autonomic	Resting blood pressure and heart rate	*How proportionately does the system respond, and how quickly does it return?*	Heart-rate recovery at 1 and 2 min; orthostatic stabilization time; HRV under standardized conditions
Musculoskeletal	Grip strength, gait speed, VO_2	*How much function is lost after stress, and how much is regained?*	Serial gait speed, grip strength and chair-rise across illness, surgery or bed rest
Immune	CRP, leukocyte count, cytokines	*Can inflammation activate proportionately and then resolve?*	Longitudinal inflammatory trajectories; time to resolution after infection; immune-competence indices
Cognitive	MoCA, MMSE, neuropsychometry	*How vulnerable is cognition to stress, and how completely does it return?*	Serial cognition around hospitalization, anesthesia or infection; delirium incidence and duration
Interoceptive / neurobehavioral	Symptom scales	*Are internal signals perceived and behaviorally integrated?*	Interoceptive accuracy tasks; autonomic–behavioral coupling; symptom-recognition latency
Relational	Social history	*Can connection and participation be maintained or restored after illness?*	Isolation and loneliness indices; caregiver network; return to participation after an index event
Patient-valued function	ADLs / IADLs	*Can this person continue what matters to them?*	Individualized goal attainment; return to named valued activities
Biological aging	Epigenetic and proteomic clocks	*Do molecular changes correspond to improved adaptive performance?*	Validated clocks correlated against dynamic recovery outcomes

Table 1. Domains of adaptive coherence.

Each domain is currently assessed in clinical practice by a state measurement (column 2). Adaptive Longevity Medicine reframes each as a question about response and return (column 3), assessed by trajectories rather than single values (column 4). The domains are proposed as an interpretable profile, not a composite score; premature compression into a single number would reproduce the reductionism the framework exists to resist. CGM, continuous glucose monitoring; HRV, heart-rate variability; ADLs / IADLs, (instrumental) activities of daily living.

7. Recovery Kinetics: From State Measurement to Dynamic Phenotyping

The central methodological proposal of ALM is **dynamic phenotyping**: measuring the organism's response to perturbation and the trajectory of its return, rather than its value at rest.

For any measured function F — gait speed, cognition, glycemic control, inflammatory markers, sleep efficiency, daily step count — a recovery episode can be characterized by seven parameters:

1. **Baseline** (F_0): the pre-stressor level, ideally established from repeated prior measurement rather than a single value.
2. **Depth of decrement** (ΔF): the magnitude of loss following the stressor.
3. **Time to nadir** (t_n): how quickly the system reaches its worst point.
4. **Initial recovery rate** (dF/dt): the slope of early return.
5. **Time to defined recovery** (t_{50}, t_{90}): the interval required to regain 50% or 90% of baseline.
6. **Completeness of recovery** ($F\infty$ / F_0): the asymptote as a fraction of baseline.
7. **Residual deficit**: the new, lower baseline established when recovery is incomplete.

The term **recovery half-life** is conceptually useful, though biological recovery is rarely a clean exponential and the analogy should not be pressed into a formalism it cannot bear. The point is not mathematical elegance. The point is a change in the clinical question, from *what is the patient's state* to *what happens to this patient over time when the system is challenged*.

Two features of this framework deserve emphasis. First, **coordination is itself a variable**. In a young system, domains recover roughly in parallel. My clinical impression — and it is stated here as a hypothesis, not a finding — is that the earliest signature of lost adaptive coherence is not slower recovery in any single domain but *decoupling* between domains: the patient whose inflammatory markers normalize in five days while their gait takes eleven weeks and their sleep never reconsolidates. A dispersion statistic across domain recovery times may prove more sensitive than any individual trajectory.

Second, the measurement burden is lower than it appears. Wearable sensors, home blood-pressure devices, activity monitors, sleep trackers, and digital cognitive assessment already generate longitudinal data continuously; what is missing is not instrumentation but a clinical construct that tells us which segments of those streams to read and against what baseline. Technology should serve the construct rather than define it. A smartphone-derived metric does not become clinically important merely because it can be collected without effort, and a great deal of what is currently sold as personalized longevity monitoring consists of exactly that fallacy.

8. The Adaptive Coherence Profile

The next step is not another biological-age score. It is an **Adaptive Coherence Profile (ACP)**: a multidimensional, openly published, non-proprietary research instrument whose components are individually interpretable.

A single composite index may eventually be justified — but only if empirical data show that the domains share sufficient structure and that the composite predicts meaningful outcomes better than its parts. Until then, compression is a marketing decision disguised as an analytic one.

A prototype ACP would contain four levels.

Level 1 — Established clinical risk and function. Blood pressure; glycemic status; lipids; smoking; renal function; established cardiovascular disease; multimorbidity; medication burden and anticholinergic load; gait speed; grip strength; falls history; cognition; hearing and vision.

Level 2 — Dynamic physiological recovery. Exertional and heart-rate recovery; orthostatic response; postprandial metabolic recovery; recovery of activity and sleep after disruption; documented recovery trajectory after the most recent illness or hospitalization.

Level 3 — Selected biological aging measures. Validated epigenetic and proteomic measures, inflammatory signatures, and organ-specific clocks, included only where analytical and clinical validity are adequate and reported with their uncertainty [13,14,15].

Level 4 — Realized human function. Independence; participation; social connection; caregiver situation; patient-defined goals; quality of life; capacity to continue named valued activities.

The purpose of the ACP is not to tell a patient they are seven years younger than their birth certificate. It is to identify **where adaptive reserve is being lost, and in what order** — which is a clinically actionable finding, because the domains in Levels 1, 2, and 4 are precisely the ones we know how to intervene upon.

9. Clinical Architecture: Five Tiers

Adaptive Longevity Medicine does not begin with an experimental gerotherapeutic. It begins by exhausting what is already known to work, in a deliberate order. The order is an ethical claim as much as a clinical one, because the most profitable intervention should never become the first intervention by default.

9.1 Tier 1 — Proven Healthspan Foundations

Regular physical activity and resistance training [39,40,41]; cardiovascular risk reduction; smoking cessation; adequate protein and overall nutritional quality; prevention and treatment of diabetes; diagnosis and treatment of sleep disorders; vaccination; correction of hearing and vision impairment; osteoporosis treatment and fall prevention; systematic medication review and deprescribing; identification and remediation of social isolation [47]; and competent management of established disease.

None of this is intellectually thrilling. All of it is clinically decisive. A longevity clinic that offers whole-body MRI and multi-omic profiling to a patient with untreated hypertension, unaddressed hearing loss, six anticholinergic medications, and no one to call at night has inverted the entire hierarchy of evidence, and has done so in a direction that happens to be commercially convenient.

9.2 Tier 2 — Preservation of Reserve

The second tier concerns detecting declining capacity before disability becomes fixed. Here conventional geriatric assessment, intrinsic capacity screening, physical performance testing, and frailty measurement carry the load [5,29,30,31,32].

The framing shifts, however. Exercise is no longer preventive advice; it is a prescription to bank reserve against a future stressor. Nutrition matters partly through its effect on the strength that will be needed during recovery. Hearing intervention matters because communication, cognition, participation, and independence are not separable. The operative question in this tier is concrete and answerable:

How much reserve does this patient need in order to survive the next stressor without losing independence — and do they have it?

9.3 Tier 3 — Recovery-Centered Care

When the stressor arrives — infection, surgery, hospitalization, a fall, bereavement, medication toxicity, a fortnight of immobility — the therapeutic objective changes, and this is where current practice fails most completely.

Discharge is not recovery. Normal laboratory values are not recovery. Absence of fever is not recovery. This is where convalescence becomes clinically operational rather than nostalgic [10]. Post-acute care should measure and document whether the patient is returning toward prior mobility, cognition, sleep, nutrition, confidence, social participation, and valued activity — and should treat failure to return as a clinical event requiring intervention, not as an expected feature of being old.

Two of my earlier arguments apply directly. Contextual error — the failure to incorporate the patient's actual life circumstances into a clinically correct decision — is nowhere more consequential than at discharge, where a physiologically appropriate plan can be functionally impossible [53]. And the coercive structures that shape post-acute placement deserve the same scrutiny I have applied to hospice referral, where the language of comfort can conceal a transfer of decisional authority away from the patient [54].

9.4 Tier 4 — Experimental Geroscience Interventions

Senolytics, nutrient-sensing modulators, partial cellular reprogramming, and other gerotherapeutics represent a serious research frontier [2,3]. Their clinical role should depend on trials demonstrating acceptable safety and effects on clinically meaningful endpoints. Validated aging biomarkers may substantially accelerate such trials, and this is their most defensible near-term use [13,14,15]. But acceleration of the search for benefit is not the same as substitution for its demonstration — a distinction the CALERIE result makes vivid [16].

9.5 Tier 5 — Relational and Experiential Interventions

Music, psychotherapy, contemplative practice, narrative and life-review work, spiritual care, structured social intervention, and the deliberate cultivation of therapeutic presence have a legitimate place in a whole-person longevity framework. I have written about music in the therapeutic encounter [55] and about the tension between evidence-based practice and spiritual frameworks that I regard as productive rather than fatal [56].

These approaches require disciplined claims, and I hold my own to the same standard. They should be evaluated against outcomes they can plausibly influence: anxiety, mood, pain, autonomic regulation, sleep, adherence, perceived isolation, quality of life, caregiver burden, and participation. They should not be marketed as life-extending. The claim I am prepared to defend is narrower and, in the setting of aging, more important: that these interventions operate on the conditions under which a person is willing and able to recover — and that at the end of life they become the whole of what medicine has to offer [57].

10. The Longevity Commons

The preceding sections reveal a structural paradox that I regard as the political heart of the matter.

Many of the most reliable determinants of healthy aging are difficult to own. Exercise can be commercialized but does not belong to anyone. Sleep is not proprietary. Human connection cannot be patented. Purpose has no intellectual-property protection. A community cannot be dispensed in a bottle. Clean air, safe streets, accessible transit, affordable protein, continuity of primary care, and the opportunity for meaningful activity all operate largely outside the pharmaceutical model — and their absence falls hardest on the patients who can least absorb it [58].

I call these collectively the **Longevity Commons**. The concept extends arguments I have made about profit-centered healthcare and about what an economy of care organized around something other than extraction would look like [59,60].

The claim is narrow and I want it stated without romance. It is not that commercial entities cannot improve longevity; they demonstrably have. It is not that non-commercial interventions are pure; they carry their own ideological freight. It is only this: because the commercial value of an intervention and its importance to human health are independent variables, a rational research ecosystem must deliberately fund the clinically important questions whose answers yield no proprietary product. Otherwise the literature becomes exquisitely detailed precisely where the incentives are strongest, and thin precisely where the largest population-level gains lie. That asymmetry is not a conspiracy. It is arithmetic. And correcting it is a matter of justice as much as of science [61].

11. A Falsifiable Research Program

A framework that cannot fail is not a scientific proposal. What follows is the minimum design that would allow Adaptive Longevity Medicine to be tested and, if it deserves it, discarded.

11.1 Phase 1 — Construct development

A prospective cohort of adults aged approximately 55–85, recruited across a range of baseline health states, undergoing assessment of comorbidity, medication burden, frailty, WHO intrinsic-capacity domains, gait speed, grip strength, balance, cardiorespiratory fitness, cognition, sleep, social connection, interoceptive measures, patient-named valued activities, conventional biomarkers, and selected validated aging biomarkers. Repeated measurement at short intervals establishes each participant's baseline *variability*, without which no subsequent recovery curve can be interpreted.

11.2 Phase 2 — Standardized perturbation

Low-risk standardized challenges: supervised submaximal exercise; supine-to-standing transition; a standardized meal challenge; a controlled cognitive load; a single night of modest sleep restriction in appropriately screened participants. The objective is to characterize the magnitude, coordination, and rate of response and return, and to determine whether individuals demonstrate reproducible adaptive phenotypes — the question on which the whole construct turns.

11.3 Phase 3 — Natural stressors

Participants are then followed prospectively through respiratory infection, surgery, hospitalization, falls, bereavement, and periods of immobility, with pre- and post-event measurement of every domain. This phase is the scientific core, because the natural stressor is both the exposure and the assay.

11.4 Phase 4 — Outcome validation

Endpoints: incident disability; loss of independent living; hospitalization and readmission; falls; cognitive decline and incident dementia; major cardiovascular events; institutionalization; mortality; and — given equal weight — loss of patient-defined function, which requires that valued activities be named at baseline while the patient can still name them [62].

Three hypotheses follow, all falsifiable:

H1. Multidomain adaptive-recovery measures predict subsequent healthspan outcomes independently of chronological age, conventional disease burden, static frailty measures, and validated biological aging biomarkers.

H2. Deterioration in recovery efficiency precedes sustained deterioration in conventional static measures — that is, the dynamic signal is earlier than the static one.

H3. Decoupling of recovery trajectories across domains predicts adverse outcomes better than the mean recovery time across those domains.

If H1 fails, adaptive coherence is a redundant relabeling of frailty and should be abandoned. If H2 fails, the framework retains explanatory but not anticipatory value. If H3 fails, coherence in the strict sense is not doing the work I claim for it, and the model reduces to multidomain resilience — which would still be useful, but would not be new.

12. The Crucial Experiment

The sharpest test of the framework is interventional, and it can be stated as a pair of scenarios that any geriatrician will recognize.

Suppose an intervention improves an epigenetic aging measure. Has health improved? ALM insists on asking six further questions: Did physical reserve increase? Did cognition improve? Did recovery after physiological stress accelerate? Did incident disability decrease? Did hospitalization decrease? Did patient-valued function improve? If the answer to all six is no, then what improved was the assay.

Now reverse it. Suppose a twelve-week supervised resistance program substantially improves strength, balance, cardiovascular recovery, and post-illness resilience, and preserves independence — while producing only a trivial change in a given methylation clock. Which intervention has produced the more meaningful anti-aging effect?

I take the answer to be obvious, and I take the fact that it is not obvious *within current longevity practice* to be the strongest available evidence that commercial epistemic distortion is operating. The answer should not be determined by which outcome is easier to sell.

13. Safeguards for Longevity Research and Practice

Because longevity medicine is unusually exposed to distortion, translation should be accompanied by explicit protections. I propose seven.

1. *Preregistration* of outcomes, subgroup analyses, and — critically — the biomarker

hierarchy, specifying in advance which measure counts as primary, so that the clock that happens to move cannot be promoted after the fact.

2. Complete reporting, including negative findings and, especially, discordance between biomarker and clinical outcomes. The CALERIE pattern of clocks disagreeing should be reported routinely rather than resolved by selective emphasis [16].

3. Separation of predictive from surrogate claims. A biomarker associated with mortality must not be marketed as a validated treatment target.

4. Transparent conflicts of interest across researchers, reference laboratories, supplement companies, biotechnology firms, and the clinics that order the tests — including the increasingly common case in which the entity interpreting the assay also sells the intervention.

5. Clinically meaningful endpoints in every trial: function, disability, cognition, hospitalization, quality of life, and patient-defined outcomes, not biological age alone.

6. Open validation. Where an aging score influences clinical decisions, its algorithm, reference population, and uncertainty must be independently replicable. A proprietary score that determines treatment is a clinical decision made by a party with a financial interest and no accountability.

7. Refusal of fear-based marketing. Chronological aging should not be medicalized into a disease state in order to manufacture perpetual consumers. The goal is the extension of healthspan, not the commercialization of the fear of death — and a profession that cannot hold that line has already lost the argument about what it is for [63].

14. Relationship to my Previous Thought

Adaptive Longevity Medicine is a convergence rather than a departure, and it may be useful to say plainly which earlier threads it gathers.

The critique of pharmaceutical incentives raised the possibility that economic structures shape what medicine studies and values [9,19,20,21]. The work on evidence distortion argued that clinical knowledge does not arrive at the physician through an economically neutral channel [20]. The epistemology of clinical judgment extended this to the relationship between measurement, language, institutional power, and what medicine is prepared to recognize as knowledge [25,26,27].

The work on transformative and embodied practice argued that technical expertise becomes incomplete when severed from embodiment, narrative, and relationship [45,46], and the hermeneutic account of the patient as a text requiring interpretation rather than extraction supplies the reading practice this framework needs at the bedside [52]. Interoception was the physiological hinge of that argument [45]; it reappears here as a domain of adaptive coherence.

But the essay that matters most to this theory is the smallest one: the question of what happened to convalescence [10]. It identified a neglected territory *between* illness and health. Adaptive Longevity Medicine gives that territory a geroscientific interpretation. Convalescence is not merely a lost social institution or a nineteenth-century sanatorium. It may be the clinical observation of a fundamental biological variable:

The Capacity to Return.

Limitations

Several limitations require emphasis, and I would rather state them than have them stated for me.

First, adaptive coherence is a theoretical construct, not a validated measure. Nothing in this paper should be used to justify a clinical product.

Second, the domains overlap substantially with frailty, intrinsic capacity, physical resilience, physiological reserve, and intrinsic health [6,29,30,31,32]. The framework earns its place only by demonstrating incremental predictive or explanatory value. Renaming is not theory.

Third, dynamic testing is practically demanding. Recovery trajectories require repeated measurement, a defensible definition of baseline in the presence of substantial intra-individual variability, standardized stressors that are safe in frail populations, and analytic methods capable of handling irregularly sampled, individually varying curves. These are real obstacles, not rhetorical ones.

Fourth, relational health, meaning, and patient-defined outcomes are heavily confounded by culture, socioeconomic position, illness severity, and reverse causation. Including them in a clinical model is not evidence that manipulating them extends life,

and I have tried throughout to mark that boundary explicitly.

Fifth, the critique of commercial incentives must itself remain disciplined. Sponsorship does not invalidate a study; non-commercial research is not free of bias; and a framework that explains every inconvenient finding by reference to industry influence has become unfalsifiable and therefore useless. The remedy for distortion is transparency, replication, complete reporting, and independent validation — not suspicion.

Sixth, and most importantly for patients, this model could do harm if implemented badly. Continuous measurement can convert healthy adults into anxious patients, and a procedural culture that measures everything and attends to no one is a form of harm I have described elsewhere [64]. Any proposed metric must demonstrate that knowing the result changes management and improves outcome; absent that, it is surveillance with a clinical vocabulary. The proper posture toward a new measurement is the one I have argued belongs at the center of clinical practice generally — a disciplined willingness not to know [65].

15. Discussion

Medicine is being offered an unusual opportunity, and the terms on which it accepts are still open.

For most of its history medicine addressed aging indirectly, through its diseases. Geroscience now offers shared upstream mechanisms [1,2], and biological aging measurement may soon allow those mechanisms to be tracked before disease declares itself [3,4,12]. Greater technical power, however, makes the underlying clinical philosophy more important rather than less, because a powerful instrument pointed at the wrong target produces confident error at scale.

Two failure modes are available. In the first, medicine defines aging as what the laboratory can measure, and the future of longevity becomes an expanding catalogue of molecular targets and proprietary scores sold to the anxious and the affluent. In the second, medicine recoils from molecular geroscience into a vague holism and abandons one of the most promising developments in modern biology. Both would be losses, and the second would be the greater one.

Adaptive Longevity Medicine proposes a third position. Molecular measures remain important. Frailty remains important. Intrinsic capacity remains important. Disease prevention, exercise, metabolic health, cognition, and cardiovascular risk remain important. But all of them are organized around a deeper clinical question:

How much capacity does this person retain to absorb the next disruption and return?

The question is inherently longitudinal, and it recognizes a feature of clinical aging that every geriatrician encounters weekly and no current metric captures. Two patients survive the same pneumonia. One goes home, regains strength, resumes his relationships, and re-enters his life. The other survives biologically and never returns to himself — he is discharged, he is alive, he is counted as a success, and his family will tell you that the man they knew did not come back from the hospital.

Mortality statistics record both as survivors. A clinical science of longevity that cannot distinguish them is not yet a clinical science.

16. Conclusion

The most important achievement of longevity medicine may not be making a molecular measure appear younger. It may be preserving the capacity of the organism — and of the person — to recover.

Aging can therefore be understood not only as accumulated molecular damage but as progressively diminished adaptive range: slower response, degraded coordination, incomplete repair, and the failure to regain prior function after stress. The construct of adaptive coherence attempts to capture that dynamic property without discarding the molecular biology, and its clinical orientation is simple enough to be carried into a consultation room:

Measure what happens after perturbation. Determine how much function returns. Identify which systems fail to return together. Intervene before incomplete recovery hardens into permanent disability. And keep, alongside the molecular data, the question that separates healthspan from mere survival — *can this person still live the life that matters to them?*

The future clinical question in aging may therefore need to move beyond

How old are your cells?

toward

When life disturbs the system, how much of you comes back?

That question can be asked at a bedside, answered with a stopwatch and a conversation, and validated against outcomes that patients themselves recognize. It restores time — the physician's oldest instrument and the one most thoroughly abolished by modern practice — to the center of the clinical encounter [66]. And it gives longevity medicine an achievable and ethically defensible goal: not endless life, but the preservation of the capacity for life.



Figure 1. *The Adaptive Longevity Model*



Figure 2. *Aging as Progressive Failure of Recovery*

The proposed clinical shift: from measuring *distance from normal* to measuring *capacity to return*.

17. References

1. Kennedy BK, Berger SL, Brunet A, Campisi J, Cuervo AM, Epel ES, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709-13. doi:10.1016/j.cell.2014.10.039.
2. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243-78. doi:10.1016/j.cell.2022.11.001.
3. Wyss-Coray T, Topol EJ. Biological aging clocks in health and disease. Nat Med. 2026;32(7):2383-94. doi:10.1038/s41591-026-04495-3.
4. Oh HS, Rutledge J, Nachun D, Pálovics R, Abiose O, Moran-Losada P, et al. Organ aging signatures in the plasma proteome track health and disease. Nature. 2023;624(7990):164-72. doi:10.1038/s41586-023-06802-1.
5. World Health Organization. World Report on Ageing and Health. Geneva: World Health Organization; 2015.
6. Cohen AA, Picard M, Beard JR, Belsky DW, Herbstman J, Kuryla CL, et al. Intrinsic health as a foundation for a science of health. Sci Adv. 2025;11(25):eadu8437. doi:10.1126/sciadv.adu8437.
7. Demaria M. Longevity clinics: between promise and peril. Aging (Albany NY). 2025;17(10):2452-4. doi:10.18632/aging.206330.
8. Gilmore AB, Fabbri A, Baum F, Bertscher A, Bondy K, Chang HJ, et al. Defining and conceptualising the commercial determinants of health. Lancet. 2023;401(10383):1194-213. doi:10.1016/S0140-6736(23)00013-2.
9. Ungar-Sargon J. The Profit Paradox: a critical review of pharmaceutical industry practices in modern medicine. Int J Nurs Healthc. 2025;1(1):1-13.
10. Ungar-Sargon J. Between illness and health: what happened to convalescence? Adv Med Clin Res. 2024;5(1):62-7.
11. Belsky DW, Caspi A, Corcoran DL, Sugden K, Poulton R, Arseneault L, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420. doi:10.7554/eLife.73420.
12. Kivimäki M, Frank P, Pentti J, Jokela M, Nyberg ST, Blake A, et al. Proteomic organ-specific ageing signatures and 20-year risk of age-related diseases: the Whitehall II observational cohort study. Lancet Digit Health. 2025;7(3):e195-e204.
13. Moqri M, Herzog C, Poganik JR, Justice J, Belsky DW, Higgins-Chen A, et al. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. 2023;186(18):3758-75. doi:10.1016/j.cell.2023.08.003.
14. Moqri M, Herzog C, Poganik JR, Ying K, Justice JN, Belsky DW, et al. Validation of biomarkers of aging. Nat Med. 2024;30(2):360-72. doi:10.1038/s41591-023-02784-9.
15. Herzog CMS, Goeminne LJE, Poganik JR, Barzilai N, Belsky DW, Betts-LaCroix J, et al. Challenges and recommendations for the translation of biomarkers of aging. Nat Aging. 2024;4:1372-83. doi:10.1038/s43587-024-00683-3.
16. Waziry R, Ryan CP, Corcoran DL, Huffman KM, Kobor MS, Kothari M, et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nat Aging. 2023;3(3):248-57. doi:10.1038/s43587-022-00357-y.
17. Ungar-Sargon J. Beyond chemical reductionism: how new depression research supports embodied medicine. Am J Med Clin Res Rev. 2025;4(8):1-17.
18. Ungar-Sargon J. Worn out philosophical ideas still pervade the practice of medicine: the Cartesian split lives on. Int J Phys Med Rehabil. 2024;1(3):1-10. doi:10.51626/ijpmr.2024.01.00012.
19. Ungar-Sargon J. A critical review of pharmaceutical industry fraudulent practices. Chem Pharm Res. 2025;7(1):1-12.
20. Ungar-Sargon J. Evidence distortion and clinical decision-making: how placebo and nocebo effects mediate industry influence in prescribing practices. J Behav Health. 2025;14(2):1-9.
21. Ungar-Sargon J. Capitalism and health care: a critique. Japan J Med Sci. 2024;5(1):174-84.
22. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017;2:MR000033. doi:10.1002/14651858.MR000033.pub3.
23. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-60. doi:10.1056/NEJMsa065779.
24. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. doi:10.1371/journal.pmed.0020124.
25. Ungar-Sargon J. The epistemology of clinical judgment: language, power, and the social construction

of medical knowledge. Jpn J Med Res. 2025;3(4):1-14. doi:10.33425/2993-6799.1032.

26. Ungar-Sargon J. The self-serving loop: ideology, institutional violence, and the manufacture of truth in religious and medical collectives. EC Neurol. 2025;Review Article:1-11.

27. Ungar-Sargon J. Reimagining healthcare through actor-network theory: a Latourian critique of modern medical hierarchies. Am J Med Clin Sci. 2025;10(2):1-7.

28. Ungar-Sargon J. Navigating the boundaries: dialogical medical practice and the challenge of pseudoscience. Am J Med Clin Res Rev. 2025;4(6):1-6.

29. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-56. doi:10.1093/gerona/56.3.m146.

30. Gijzel SMW, Whitson HE, van de Leemput IA, Scheffer M, van Asselt D, Rector JL, et al. Resilience in clinical care: getting a grip on the recovery potential of older adults. J Am Geriatr Soc. 2019;67(12):2650-7. doi:10.1111/jgs.16149.

31. Colón-Emeric C, Schmader K, Cohen HJ, Morey M, Whitson H. Ageing and physical resilience after health stressors. Stress Health. 2023;39(S1):48-54. doi:10.1002/smi.3241.

32. Chhetri JK, Harwood RH, Ma L, Michel JP, Chan P. Intrinsic capacity and healthy ageing. Age Ageing. 2022;51(11):afac239. doi:10.1093/ageing/afac239.

33. Krumholz HM. Post-hospital syndrome — an acquired, transient condition of generalized risk. N Engl J Med. 2013;368(2):100-2. doi:10.1056/NEJMp1212324.

34. Covinsky KE, Palmer RM, Fortinsky RH, Counsell SR, Stewart AL, Kresevic D, et al. Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Geriatr Soc. 2003;51(4):451-8. doi:10.1046/j.1532-5415.2003.51152.x.

35. Gill TM, Allore HG, Gahbauer EA, Murphy TE. Change in disability after hospitalization or restricted activity in older persons. JAMA. 2010;304(17):1919-28. doi:10.1001/jama.2010.1568.

36. Inouye SK, Westendorp RGJ, Saczynski JS. Delirium in elderly people. Lancet. 2014;383(9920):911-22. doi:10.1016/S0140-6736(13)60688-1.

37. Ungar-Sargon J. Time horizons and the evolving therapeutic space: a framework for age-responsive spiritual care. J Psychol Neurosci. 2025;Special Issue:1-13.

38. Ungar-Sargon J. The patient history — reimagining the body in illness. Am J Med Clin Sci. 2024;9(5):1-9.

39. Pahor M, Guralnik JM, Ambrosius WT, Blair S, Bonds DE, Church TS, et al. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. JAMA. 2014;311(23):2387-96. doi:10.1001/jama.2014.5616.

40. Fukushima N, Kikuchi H, Sato H, Sasai H, Kiyohara K, Sawada SS, et al. Dose-response relationship of physical activity with all-cause mortality among older adults: an umbrella review. J Am Med Dir Assoc. 2024;25(3):417-30. doi:10.1016/j.jamda.2023.09.028.

41. Shailendra P, Baldock KL, Li LSK, Bennie JA, Boyle T. Resistance training and mortality risk: a systematic review and meta-analysis. Am J Prev Med. 2022;63(2):277-85. doi:10.1016/j.amepre.2022.03.020.

42. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15(9):505-22. doi:10.1038/s41569-018-0064-2.

43. Ahuja SK, Manoharan MS, Lee GC, McKinnon LR, Meunier JA, Steri M, et al. Immune resilience despite inflammatory stress promotes longevity and favorable health outcomes including resistance to infection. Nat Commun. 2023;14:3286. doi:10.1038/s41467-023-38238-6.

44. Ungar-Sargon J. Reframing Alzheimer's: toward a spiritual phenomenology of memory loss. Arch Med Case Rep. 2025;6(1):1-5.

45. Ungar-Sargon J. The science of interoception and unconscious bias in healthcare: a call for embodied clinical practice. Neurol Neurosci. 2025;6(6):026.

46. Ungar-Sargon J. A framework for transformative healthcare practice. Am J Med Clin Res Rev. 2025;4(7):1-40. doi:10.58372/2835-6276.1313.

47. Wang F, Gao Y, Han Z, Yu Y, Long Z, Jiang X, et al. A systematic review and meta-analysis of 90 cohort studies of social isolation, loneliness and mortality. Nat Hum Behav. 2023;7(8):1307-19. doi:10.1038/s41562-023-01617-6.

48. Ungar-Sargon J. Sacred and profane space in the therapeutic encounter: moving beyond rigid distinctions. Am J Neurol Res. 2025;4(2):1-9. doi:10.52106/2837-7761.1025.

49. Ungar-Sargon J. Effective listening to the patient affects the outcome. J Neurol Neurosci Res. 2024;5:92-8.

50. Sutin AR, Zavala D, Milad E, Stephan Y, Karakose S, Terracciano A, et al. Purpose in life and mortality: a meta-analysis of the published literature and individual-participant data of 488,765 participants followed for up to 32 years. Psychol Med. 2026;56:e214. doi:10.1017/S0033291726104863.

51. Ungar-Sargon J. The unspoken terror: mortality awareness in clinical settings for chronic and degenerative disease. J Neurol Neurosci Res. 2025;6(1):133-7.

52. Ungar-Sargon J. Hermeneutic approaches to medicine: from objective evidence to patient as sacred text. EC Neurol. 2025;17(6):1-10.

53. Ungar-Sargon J. Contextual errors in medical decision making: reclaiming the human situation in clinical care. J Med Clin Res Rev. 2025;9(10):1-15.

54. Ungar-Sargon J. Comfort or control? A critical examination of hospice care and coercion in the modern healthcare system. Adv Med Clin Res. 2025;6(2):131-7.

55. Ungar-Sargon J. The importance and efficacy of music in the therapeutic encounter and healing: neuroscientific, mystical, and clinical perspectives. E-J Music Res. 2025;5(1):1-12. doi:10.38159/ejomur.2025511.

56. Ungar-Sargon J. Beyond reductionism or wishful thinking? Tensions between evidence-based practice and spiritual frameworks in contemporary healthcare. Trends Intern Med. 2025;5(1):1-10.

57. Ungar-Sargon J. Embodied theology for end-of-life care: a being-with-nonbeing approach to dying patients. KOS J Public Health Integr Med. 2025;1(2):1-23.

58. Ungar-Sargon J. Poverty, precarity, and the fracturing of care: toward a new model of healthcare inequity. J Psychol Neurosci. 2025;7(4):1-13.

59. Ungar-Sargon J. Toward a sacred economy of care: reimagining healthcare through an integrative moral lens. Glob J Crit Care Emerg Med. 2025;2(3):1-13.

60. Ungar-Sargon J. Healthcare without profit: an embodied theological vision. J Pharm Res Rep. 2025;6(5):1-8. doi:10.47363/JPRSR/2025(6)178.

61. Ungar-Sargon J. Healing as justice: clinical advocacy in therapeutic practice. J Med Clin Res Rev. 2025;9(6):1-10.

62. Ungar-Sargon J. Do patients have free will? A clinical-philosophical essay on adherence, addiction, and the bounds of choice. Am J Med Clin Sci. 2025;10(6):1-9.

63. Ungar-Sargon J. Against the current: reclaiming medical ethics in a system of greed. Adv Educ Res Rev. 2025;2(1):65-75.

64. Ungar-Sargon J. The architecture of medical horror: a critical analysis of procedural culture in contemporary healthcare. Med Clin Res. 2025;10(8):1-10.

65. Ungar-Sargon J. The sacred epistemology of not-knowing: uncertainty and doubt as foundations for humility in medicine and religion. Clin Rev Cases. 2026;8(1):1-8.

66. Ungar-Sargon J. The sacred temporality of healing: solitude, embodied presence, and the physician as witness. Am J Med Clin Res Rev. 2025;4(11):1-16.